Figure 1 | Scientific Reports

Figure 1

From: STAT6 promotes bi-directional modulation of PKM2 in liver and adipose inflammatory cells in Rosiglitazone-treated mice

Figure 1

Rosiglitazone treatment normalizes liver triglyceride levels and hepatocellular stress in STAT6-deficient mice.

(a) Hepatic triglyceride content, (n = 5–10/group). (b) Thiobarbituric acid reactive substances (TBARS)/Malonaldehyde (MDA) levels in liver tissue, (n = 5–8/group). (c) Protein expressions of oxidative stress-related proteins: glyoxalase 1 (GLO1) and superoxide dismutase 1 (SOD1), (n = 3–8/group). Actin is used as loading control. All graphs represent mean ± S.E.M expressed as arbitrary units normalized to the mean of the WT control mice. * = p ≤ 0.05, ** ## = p ≤ 0.01, *** ### = p ≤ 0.001 (* WT vs. STAT6-deficient mice; #Control vs. RSG-treated mice) determined by one way analysis of variance (ANOVA) test. All runs were done in parallel with the same experimental conditions.

Back to article page